967
Participants
Start Date
May 31, 2015
Primary Completion Date
November 7, 2017
Study Completion Date
November 7, 2017
1 gram Tranexamic Acid (TXA)
TXA produces an antifibrinolytic effect by competitively inhibiting the activation of plasminogen to plasmin.
2 grams TXA
TXA produces an antifibrinolytic effect by competitively inhibiting the activation of plasminogen to plasmin.
0.9% Sodium Chloride injectable
Loading dose of 0.9% Sodium Chloride solution given prior to hospital arrival followed by a placebo of 0.9% Sodium Chloride solution infusion over 8 hours after hospital arrival. No active drug is added to the solution.
Alabama Resuscitation Center, Birmingham
University of Cincinnati Medical Center, Cincinnati
Milwaukee Resuscitation Research Center, Milwaukee
St Paul Regions Hospital, Saint Paul
Hennepin County Medical Center, Minneapolis
Mayo Clinic Rochester, Rochester
Dallas Center for Resuscitation Research, Dallas
Memorial Hermann Hospital - Texas Medical Center, Houston
Harborview Medical Center, Seattle
Oregon Health & Sciences University, Portland
British Columbia Regional Coordinating Center, Vancouver
Toronto RescuNet, Toronto
Collaborators (1)
National Heart, Lung, and Blood Institute (NHLBI)
NIH
U.S. Army Medical Research and Development Command
FED
Canadian Institutes of Health Research (CIHR)
OTHER_GOV
Heart and Stroke Foundation of Canada
OTHER
American Heart Association
OTHER
Defence Research and Development Canada
INDUSTRY
University of Washington
OTHER